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E1/E2 states no PLBMean FRET (%) S.E.
PLB-Ser16Ala
Mean FRET (%) S.E.
PLB-Ser16Glu
Mean FRET (%) S.E.
TG 10.8 1.1 15.4 1.3 18.2 1.4
H+ 12.1 1.3 16.3 2.3 18.6 2.4
ATP 17.7 2.6 20.8 3.2 23.9 3.4
2Ca 16.6 1.4 20.0 1.3 23.2 2.3
2Ca+ATP 16.9 0.8 19.7 1.0 23.0 2.1
Vi 9.9 0.8 13.5 2.4 16.5 3
AlF4- 9.2 3.4 13.1 3.1 18.24 1.4
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optimize	this	experiment,	I	would	need	to	repeat	measurements	with	a	non-phosphorylated	version	of	PLB-Ser16Ala,	as	well	as	determine	the	true	ratio	of	PLB.	Another	aspect	for	optimization	would	be	determination	of	the	in-cell	SERCA:	PLB	ratio	to	determine	that	enough	PLB	is	expressed	to	overcome	PLB	pentamers	formation	and	allow	association	with	SERCA	(I	have	used	up	to	1	nM	SERCA	to	20	nM	PLB	ratio	of	constructs’	expression	for	FRET	measurements).	Overall,	PLB	seems	to	inhibit	overexpressed	SERCA	activity,	and	ER	Ca2+	stores	are	increased	for	overexpressed	SERCA	in	complex	with	PLB.		Our	FRET	structural	data	indicate	that	PLB	binding	to	SERCA	leads	to	SERCA	cytosolic	domain	compact	conformation,	which	is	further	enhanced	by	PLB	Ser16	phosphorylation	(Fig.	30A).	Based	on	the	substrate-stabilized	SERCA	intermediates	of	enzymatic	cycle	experiment,	PLB	binding	and	phosphorylation	induce	compact	conformation	in	all	transitional	states	of	Ca2+	transport	(Fig.	30C),	which	suggests	that	SERCA	compact	conformation	may	be	of	a	regulatory	significance.	To	elucidate	the	details	of	structural	aspects	of	SERCA	regulation	by	PLB,	further	investigations	are	necessary.	In	particular	Ca2+	handling	in	live	cells	in	the	presence	of	PLB	variants	are	of	great	interest,	as	well	as	extended	MD	simulation	of	SERCA-PLB	complex	spontaneous	dynamics.
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CHAPTER	FIVE	APPLICATION	OF	2-COLOR	FRET	BIOSENSORS	IN	IDENTIFICATION	OF	REGULATORY	INTERACTIONS	Our	lab	has	generated	the	2-color	SERCA	FRET	sensor	(Hou	et	al.,	2012)	which	was	used	in	this	work,	as	well	as	in	multiple	assays	aimed	to	determine	SERCA	structural	dynamics	(Blackwell	et	al.,	2016;	Hou	et	al.,	2012;	Pallikkuth	et	al.,	2013)	and	potential	substrates	(Cornea	et	al.,	2013;	Gruber	et	al.,	2014).	Additionally,	my	lab	has	demonstrated	that	the	technique	to	generate	2-color	FRET	biosensor	can	be	applied	to	other	molecules.	For	example,	2-color	MRP-1,	another	transporter	ATPase,	was	generated	and	used	in	FRET	high-throughput	screening	for	identification	of	novel	substrates	(Iram	et	al.,	2015).	For	both	SERCA	and	MRP-1	transporters,	the	most	mobile	domains	were	labeled	with	donor	and	acceptor	fluorescent	proteins	to	monitor	structural	changes	upon	interaction	with	potential	modulators.	The	identified	substrates	were	further	tested	to	determine	their	functional	effect.	Thus,	my	lab	has	developed	a	general	technique	of	2-color	FRET	biosensor	generation	which	can	be	applied	to	a	wide	variety	of	molecules.	In	support	to	this	statement,	I	will	next	describe	several	examples	of	the	2-color	FRET	biosensors	use	for	detections	and	investigations	of	regulatory	interactions.			
SERCA	and	Hax-1	Direct	Interactions	as	Assessed	by	FRET	Hax-1	has	been	shown	to	interact	with	SERCA	in	vitro	(Vafiadaki	et	al.,	2009).	Nevertheless,	the	direct	interaction	of	HAX-1	and	SERCA	in	vivo	has	not	been	observed	and	is	highly
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debated	(Vandecaetsbeek	et	al.,	2011).	To	observe	the	potential	interaction	in	cells,	I	tested	to	determine	if	Hax-1	has	an	effect	on	SERCA	intramolecular	FRET	in	AAV-293	cells	expressing	unlabeled	Hax-1	and	2-color	SERCA	(Cer	fluorophore	on	N-terminus	and	YFP	before	residue	509	within	N-domain).	I	detected	an	apparent	decrease	in	intramolecular	FRET	for	2-color	SERCA	in	the	presence	of	Hax-1	using	the	acceptor	sensitization	technique,	but	not	the	acceptor	photobleaching	method	(Fig.	33A-B).	Even	though	the	2-color	SERCA	by	itself	showed	FRET	values	similar	to	those	reported	previously	(Hou	et	al.,	2012),	the	main	concern	about	2-color	SERCA	FRET	in	the	presence	of	Hax-1	is	the	possibility	that	the	YFP	fusion	site	on	the	SERCA	N-domain	before	residue	509	can	be	too	close	to	the	proposed	Hax-1	binding	site	(Fig.	32C,	loop	consisting	of	residues	E575-V594,	red)	(Vafiadaki	et	al.,	2009;	Vandecaetsbeek	et	al.,	2011).	Binding	of	Hax-1	to	this	highly	accessible	N-domain	loop	would	result	in	Hax-1	being	physically	in	the	way	of	measuring		
	
Figure	33.	2CS	FRET	in	the	presence	of	Hax-1.		2CS	intramolecular	FRET	measured	by	(A)	the	acceptor	photobleaching	method	(n=3,	#p≤0.0001)	and	(B)	the	acceptor	sensitizing	method	(n=5,	*p=0.008	and	#p≤0.0001).	Only	the	acceptor	sensitization	assay	showed	a	significant	decrease	in	SERCA	intramolecular	FRET	in	the	presence	of	HAX1	(*).	HAX1	has	no	additive	effect	on	FRET	decrease	by	TG	(#).	
(C)	2CS	structure	shows	Cer	fluorophore	(cyan)	attached	to	A-domain	(blue),	YFP	fluorophore	(orange)	attached	to	N-domain	(yellow),	and	proposed	cytoplasmic	Hax-1	binding	sites	in	red.	
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Nevertheless,	the	detection	of	a	FRET	decrease	in	the	presence	of	HAX-1	(Fig.	33A-B)	indicates	direct	binding	of	HAX-1	to	SERCA,	and	that	this	interaction	indeed	occurs	in	live	cells.	Following	investigations	are	needed	to	determine	how	stable	this	interaction	is	and	if	there	is	a	functional	aspect	to	this	direct	association	of	HAX-1	with	SERCA.			
Analysis	of	SERCA	Association	with	DWORF	Recently	identified	by	Dr.	Eric	Olson	group	micropeptide	encoded	by	lncRNA	DWORF	has	been	proposed	to	bind	to	SERCA	in	the	same	binding	site	as	SERCA	inhibitor	PLB	as	presented	in	Fig.	34A-B,	thus	relieving	SERCA	inhibition	by	displacement	of	PLB	(Nelson	et	al.,	2016).	Nevertheless,	the	details	of	SERCA-DWORF	association	have	not	been	investigated	due	to	the	fact	that	discovery	of	DWORF	micropeptide	is	relatively	recent.	I	used	progressive	acceptor	photobleaching	FRET	measurements	to	investigate	DWORF	interaction	with	SERCA	and/or	PLB,	as	well	as	DWORF	ability	to	form	homo-dimers.	Fig.	34C	shows	that	DWORF-SERCA	complex	has	lower	FRET	compared	to	PLB-SERCA	complex	(Fig.	34D).	The	lower	FRET	can	be	explained	by	shorter	topology	of	DWORF	(Fig.	34A)	compared	to	PLB	(Fig.	34B).	PLB	truncated	all	the	way	to	TM-domain	has	been	shown	to	have	decreased	FRET	compared	to	full	length	PLB	(data	by	previous	lab	member	Phil	Bidwell,	not	published).	Plotting	Cer	vs.	YFP	resulted	in	a	linear	relationship	of	donor	and	acceptor	fluorophores	(Fig.	34E)	consistent	with	1:1	stoichiometry.	This	result	means	that	DWORF	binds	to	SERCA	as	a	monomer	to	form	a	heterodimer	(one	Cer	for	one	YFP	detected),	the	same	way	as	PLB	(Blackwell	et	al.,	2016;	Kelly	et	al.,	2008).	I	detected	no	FRET	between	DWORF-DWORF	(Fig.	34F),	consistent	with	the	suggestion	that	DWORF	is	monomeric	(Nelson	et	al.,	2016).	Additionally,	I	did	not	detect	FRET	between	DWORF-PLB	(Fig.	34G),	indicating	that	DWORF	does	not	form	hetero-oligomers	with	PLB.	Overall,	these	
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data	confirmed	DWORF	association	with	SERCA	in	1:1	stoichiometry	and	showed	that	DWORF	most	likely	exists	as	a	monomer	and	does	not	form	homo-	or	heterodimers.		 When	using	the	acceptor	sensitization	FRET	method,	DWORF-SERCA	FRET	was	also	decreased	compared	to	PLB-SERCA	FRET	(Fig	35A-B).	I	observed	smaller	Kd	of	DWORF	compared	to	PLB	(Fig.	35C),	which	indicates	that	DWORF	has	higher	apparent	affinity	for	SERCA	than	PLB.	This	observation	indicates	that	targeting	PLB	displacement	with	DWORF	overexpression	can	become	a	novel	approach	to	enhance	SERCA	activity	in	cardiac	dysfunctions.	
	
Figure	34.	Analysis	of	DWORF	homo-oligomerization	and	association	with	SERCA,	
PLB	and	itself	by	acceptor	photobleaching	FRET.	
(A)	SERCA-DWORF	complex	shows	DWORF	bound	to	the	same	groove	as	PLB	as	in	(B)	SERCA-PLB	complex.	For	(C-D,	F-H)	photobleaching	starts	at	the	black	arrow.	(C)	FRET	detected	between	Cer-SERCA	and	YFP-PLB.	(D)	FRET	detected	between	Cer-SERCA	and	YFP-DWORF.	(E)	Plotting	Cer	fluorescence	as	a	function	of	YFP	reveals	that	both	the	FRET	complexes,	SERCA-PLB	and	SERCA-DWORF,	are	heterodimers.	(F-G)	No	FRET	detected	between	Cer-DWORF	and	YFP-DWORF	(F)	or	YFP-PLB	(G).	(H)	FRET	detected	between	Cer-PLB	and	YFP-PLB	represents	PLB	homo-oligomerization.	Error	bars	represent	SD,	n=6-16.		
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To	investigate	if	DWORF	competes	with	PLB	for	association	with	SERCA,	I	performed	competition	experiments.	Specifically,	I	measured	FRET	between	Cer-SERCA	and	YFP-PLB	in	the	presence	of	increasing	DWORF	expression.	The	maximal	SERCA-to-PLB	FRET	was	progressively	decreased	by	increased	co-expression	of	DWORF	(Fig.	35D-E),	which	indicated	that	DWORF	indeed	competes	with	PLB	for	the	same	binding	site.	Since	I	have	shown	that	DWORF	does	not	oligomerize	with	PLB	(Fig.	34G),	this	decrease	is	not	due	to	PLB	being	sequestered	away	from	SERCA	into	DWORF-PLB	hetero-oligomeric	complexes.	Additionally,	I	saw	a	progressive	decrease	in	the	apparent	PLB-to-SERCA	Kd	
	
Figure	35.	Analysis	of	DWORF	association	with	SERCA	by	acceptor	sensitizing	FRET.	
(A)	Representative	data	for	FRET	detected	between	Cer-SERCA	and	YFP-DWORF	or	YFP-PLB.	(B)	Quantification	of	relative	maximal	FRET	in	(A).	(C)	Quantification	of	Kd	FRET	in	(A).	(D)	Representative	data	set	for	competing	PLB	off	with	DWORF.	Ratios	represent	molar	ratio	of	PLB	to	DWORF	DNA	constructs	used	for	transient	transfection	of	AAV-293.	
(E)	Quantification	of	relative	maximal	FRET	in	(D).	(F)	Quantification	of	Kd	in	(D).	Error	bars	present	SD,	n=3.			
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parameter	(Fig.	35F).	This	result	indicates	that	PLB’s	apparent	affinity	to	SERCA	increases	in	the	presence	of	DWORF.	This	is	exactly	what	I	would	expect	if	PLB	is	competed	away-	a	positive	correlation	between	an	increased	number	of	free	PLB	molecules	and	their	affinity	for	SERCA.	With	the	present	FRET	measurements,	I	still	cannot	exclude	the	possibility	that	DWORF	binds	to	SERCA	at	different	from	the	PLB	binding	site(s)	and	alters	SERCA-PLB	complex	structure	which	results	in	a	FRET	decrease.	Further	investigations	are	needed	to	determine	the	details	of	structural	regulations	of	SERCA	activity	by	DWORF.	Overall,	I	confirmed	that	DWORF	binds	to	SERCA	with	higher	affinity	than	PLB	(Fig.	35C)	most	likely	at	the	same	binding	site	(Fig.	35D-E)	in	one	to	one	ratio	(one	DWORF	molecule	per	one	SERCA)	(Fig.	34E).	I	showed	that	primarily	DWORF	exists	as	a	monomer	and	does	not	form	oligomers	with	itself	or	PLB.	Since	DWORF	positively	regulates	SERCA	activity	(Nelson	et	al.,	2016)	and	has	a	higher	affinity	to	SERCA	than	PLB	(Fig.	35C),	DWORF	is	very	likely	to	become	a	high	significance	novel	therapeutic	target	to	enhance	cardiac	function.		
Quantification	of	DOX	Uptake	by	AAV-293	Cells	to	Assess	MRP-1	Transport	Activity	2-color	SERCA	pump	has	been	successfully	used	to	identify	modulators	in	a	high-throughput	screen	of	a	library	of	biologically	active	compounds	(Gruber	et	al.,	2014).	My	lab	had	applied	the	same	labeling	technique	to	generate	2-color	multi-drug	resistance	protein-1	(MRP-1)	biosensor	with	GFP	and	TagRFP	fluorophores	attached	to	the	two	most	dynamic	cytosolic	nucleotide-binding	domains,	which	were	predicted	to	undergo	transition	from	open-to-closed	conformation	during	extrusion	of	substrates	from	the	cytosol	(Aller	et	al.,	2009).	2-color	MRP-1	FRET	measurements	were	performed	to	screen	for	and	identify	
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prospective	transporter	modulators	(Iram	et	al.,	2015).	As	a	result,	several	MRP-1	substrates	were	detected:	MK571	(known	MRP1	inhibitor),	epigallocatechin	gallate	(antioxidant),	mesalamine	(anti-inflammatory),	calcipotriol	(analog	of	vitamin	D),	and	meropenem	(antibiotic).	To	define	these	substrates’	functions,	I	tested	to	determine	if	these	compounds	are	able	to	alter	MRP-1	activity.	I	used	doxorubicin	(DOX),	one	of	the	MRP-1	substrates,	to	perform	assessment	of	MRP-1	function	in	the	presence	of	the	identified	substrates.	When	DOX	is	not	transported	out	of	the	cell,	it	accumulates	in	the	nuclei	as	detected	by	the	presence	of	red	florescence	(Fig.	36B-C,	UT).	Overexpressed	MRP-1	prevents	DOX	accumulation	in	the	nuclei	and	I	saw	great	reduction	of	red	signal	in	cells	nuclei	(Fig.	36B-C,	MRP-1).	Treatment	of	cells	with	
	
Figure	36.	DOX	uptake	in	the	nucleus	of	AAV-293	cells	in	the	presence	of	candidate	
modulators.	
(A)	Schematic	representation	of	MRP-1	structure.	Top	panel	represents	high	affinity	for	ligands	conformation	with	globular	nucleotide-binding	domains	apart,	while	bottom	panel	pictures	low	ligand-affinity	conformation.		(B)	Representative	images	of	cells	treated	with	DOX	in	the	presence	of	candidate	compound.	On	Ctrl	image	several	untransfected	(UT)	cells	are	marked	with	white	arrows,	while	several	MRP-1	expressing	cells	are	marked	with	green	arrows.	(C)	Quantification	of	red	fluorescence	intensities	was	used	as	an	index	of	nuclei	DOX	accumulation.	Values	are	±	S.E.M,	normalized	to	UT	cells	in	the	same	microscopic	field.	*P	<	0.0001	versus	UT;	#P<	0.0001	versus	“Ctrl”	MRP-1	alone.	All	error	bars	represent	±	S.E.M.			
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known	MRP-1	inhibitor	MK571,	one	of	the	high-throughput	screening	hits,	resulted	in	DOX	accumulation	in	cells’	nuclei	as	would	be	expected	for	a	transporter	inhibitor.	Calcipotriol	inhibited	MRP-1	transport	comparable	to	MK571	with	similar	DOX	levels	detected	in	cells’	nuclei	(Fig.	36B-C,	calcipotriol).	Since	calcipotriol	is	a	vitamin	D	analog,	this	result	explains	the	fact	that	vitamin	D	has	been	demonstrated	to	potentiate	the	effect	of	chemotherapeutic	agents	(Ma	et	al.,	2010).	Epigallocatechin	gallate	and	meropenem	exhibited	no	effect	on	MRP-1	transport	activity,	even	though	they	induced	structural	changes	to	MRP-1	organization	in	preceding	high-throughput	screening.	Mesalamine	interfered	with	DOX	redistribution	in	UT	cells,	and	was	not	used	to	evaluate	MRP-1	function	(Fig.	36B-C,	mesalamine).	Overall,	I	was	able	to	confirm	two	hit	compounds	as	MRP-1	inhibitors,	MK571	and	calcipotriol,	which	demonstrated	the	potential	of	utilizing	2-color	FRET	sensors	in	combination	of	high-throughput	screening	analysis	with	functional	assay	in	order	to	identify	novel	modulators	of	protein	of	interest.	This	technique	has	a	potential	to	become	a	powerful	tool	in	clinical	drug	discovery.
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CHAPTER	SIX	DISCUSSION	While	SERCA	is	one	of	the	major	regulators	of	Ca2+	handling	in	the	heart,	and	thus	the	ideal	target	to	improve	cardiac	function	(Hayward	et	al.,	2015;	Inesi	et	al.,	2008),	at	the	moment,	no	successful	therapeutic	approaches	have	been	developed	to	increase	SERCA	activity.	The	promising	gene	therapy	clinical	trials	designed	to	increase	SERCA	expression	in	patients’	failing	hearts	have	not	yet	achieved	success	in	improving	patients’	cardiac	function	(Zsebo	et	al.,	2014)	and	highlighted	the	apparent	lack	of	understanding	of	SERCA	structure	and	function.	One	of	the	goals	of	this	work	was	to	contribute	to	understanding	of	SERCA	function	via	thorough	investigation	of	SERCA	structural	dynamics	during	Ca2+	transport.	The	strength	of	the	current	study	was	in	a	combination	of	in	silico,	in	vitro,	and	ex	vivo	assays	that	resulted	in	a	detailed	evaluation	of	SERCA	structural	and	regulatory	dynamics.		
Structural	Dynamics	of	WT-SERCA	During	Ca2+	Transport	SERCA	FRET	measurements	in	a	substrates-stabilized	environment	allowed	identification	of	SERCA	headpiece	structural	conformers	for	several	intermediate	states	during	Ca2+	transport	(Fig.	15).	I	modified	a	Post-Alberts	reaction	cycle	by	adding	my	FRET	data	and	emphasizing	states	with	similar	intramolecular	FRET	efficiencies	in	blue	boxes:	SERCA	high-calcium	affinity	E1	states	(yellow)	are	presented	by	compact	conformers	(~15%	FRET),	while	SERCA	low-calcium	affinity	E2	states	(green)	have	more	open	headpiece	conformation	(~8%	and	~10%	FRET)	during	specific	cycle	steps	(Fig.	16).
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Figure	16	presents	SERCA	ground	protonated	state	E2	and	biochemically	equivalent	TG-bound	state	(E2-TG)	(Satoh	et	al.,	2011;	Toyoshima	et	al.,	2000),	both	of	which	displayed	low	FRET	states	(~10%)	suggesting	SERCA	open	conformers.	These	in	vitro	results	were	confirmed	by	ex	vivo	measurements	of	SERCA	structural	conformation	in	cells,	where	TG	also	sequestered	SERCA	population	into	low	FRET	state	(Fig.	17B).	Thus,	both	measurements	consistently	resulted	in	detection	of	low	FRET.	On	the	other	hand,	SERCA	biochemically-stabilized	intermediate	states	of	enzymatic	cycle	representing	physiological	Ca2+	bound	states	E1-2Ca-ATP	and	E1P-2Ca,	as	well	as	non-physiological	state	E1-2Ca,	all	displayed	high	FRET	states	(~15%)	characterizing	SERCA	closed	conformers.	I	also	detected	high	2-color	SERCA	FRET	in	AAV-293	cells	treated	with	Iono	(Fig.	17C,	black).	However,	I	observed	low	FRET	during	spontaneous	Ca2+	release	events	(Fig.	18B).	Here,	I	will	elaborate	on	these	apparently	inconsistent	observations,	which	are	actually	the	major	findings	of	this	work.	To	resolve	the	deceptive	discrepancies	of	the	detected	FRET	changes	in	response	to	intracellular	Ca2+	oscillations	in	cells,	I	treated	cells	with	Iono	after	detection	of	the	spontaneous	anti-correlated	FRET	and	cytosolic	Ca2+	fluctuations	(Fig.	19A).	Figure	37,	left	panels,	shows	a	schematic	representation	of	one	spontaneous	anti-correlated	FRET/Ca2+	change	and	FRET	biphasic	response	to	Iono	treatment.	High-starting	SERCA	FRET	(Fig.	37A,	blue	arrows)	was	observed	in	live	cells,	which	are	characterized	by	low	basal	Ca2+	(up	to	200	nM)	and	high	ATP	(up	to	5mM).	Thus,	SERCA	is	saturated	with	ATP	but	not	Ca2+	(Fig.	37A,	E1-ATP),	the	same	conditions	as	in	non-muscle	cells	and	in	relaxed	muscle	cells.	I	observed	high	SERCA	FRET	in	microsomal	preparations	when	both	ATP	and	Ca2+	were	high	(Fig.	15B	and	Fig.	16,	E1-2CA-ATP).	However,	in	the	cells	during	intracellular	
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Ca2+	oscillations,	I	observed	low	FRET	upon	cytosolic	Ca2+	increase	(Fig	18B).	Numerous	reports	suggested	that	exposure	to	low	Ca2+	shifts	ATP-bound	SERCA	(E1-ATP)	into	high-affinity	conformer	primed	for	efficient	Ca2+	binding	and	transport	upon	major	Ca2+	influx	(Inesi	et	al.,	2006;	Jensen	et	al.,	2006;	Mintz	et	al.,	1995).	Thus,	SERCA	in	resting	E1-ATP	state	is	readily	activated	upon	influx	of	cytosolic	Ca2+.	In	support	to	this	statement	and	in	contrast	to	biochemically	‘fixed’	SERCA	intermediates,	in	live	cells,	where	ATP	levels	are	high,	SERCA	starts	cycling	immediately	upon	Ca2+	release	event.	However,	because	of	the	
	
Figure	37.	WT-SERCA	population	accumulates	in	states	prior	to	slow	steps	during	
transient	Ca2+	increase.	Schematic	representation	of	simultaneous	FRET	and	cytosolic	Ca2+	fluctuations	as	detected	in	Fig.	19A	is	on	the	left,	while	corresponding	transitional	steps	are	highlighted	by	blue	arrows	on	the	Post-Albers	cycle	(left	panels).	(A)	In	basal	Ca2+,	SERCA	population	is	at	resting	E1-ATP	state	(high	FRET-	open	conformers)	(B)	During	transient	Ca2+	increase,	SERCA	population	accumulates	in	E2P	prior	to	slow	Pi	release	step	(low	FRET-	open	conformers).	I	propose	the	existence	of	SERCA	Ca2+-bound	low	FRET	state	(open	conformers)	just	before	Ca2+	release	event,	another	slow	step	of	enzymatic	cycle.		
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slow	steps	in	SERCA	enzymatic	cycle,	like	during	release	of	Pi	group	(Champeil	et	al.,	1986;	Hanel	and	Jencks,	1990;	Petithory	and	Jencks,	1986),	SERCA	population	accumulates	in	E2	low	FRET	state	(open	conformers)	(Fig.	37B,	E2P).	These	conditions	occur	during	contractions	of	cardiac	or	skeletal	muscle	cells	and	in	non-muscle	cells	during	intracellular	Ca2+	waves.	Ca2+	release	was	also	identified	as	one	of	the	slow	steps	of	SERCA	enzymatic	cycle	(Fernandez-Belda	et	al.,	1984).	Based	on	this	statement	and	the	fact	that	I	detected	accumulation	of	majority	of	pumps	in	low	FRET	state,	I	propose	the	existence	of	Ca2+-bound	state,	which	is	most	likely	short-lived	and	exists	right	before	Ca2+	ions	are	released	into	ER	lumen	(Fig.	37B,	‘?’).	After	each	spontaneous	Ca2+	release	event,	probably	due	to	SERCA	function	and	temporary	inactivation	of	RyR,	cytosolic	Ca2+	concentration	drops	and	SERCA	population	returns	to	low	Ca2+/high	ATP	conformation	of	high	FRET	state	(Fig.	37A,	E1-ATP).	In	contrast	to	transient	intracellular	Ca2+	increases,	during	sustained	Ca2+	elevation	upon	Iono	treatment,	even	though	SERCA	population	originally	accumulates	in	high	Ca2+/high	ATP	low	FRET	state	(open	conformers),	the	majority	of	SERCA	pumps	gradually	shifts	into	high	FRET	state	(compact	conformers)	(Fig.	17B	and	19A).	The	immediate	decrease	in	phase	1	FRET	upon	the	addition	of	Iono	matches	the	prediction	that	the	transition	of	pumps	to	E2	conformation	(Fig.	38A)	is	the	slowest	step	of	the	Ca2+	catalytic	cycle,	and	the	majority	of	SERCA	pumps	accumulates	in	E2P	(or	anticipated	low	FRET	Ca2+-bound)	state(s).		Less	clear	was	an	increase	in	phase	2	FRET	change	observed	in	Iono-treated	cells	(Fig.	17C).	In	this	experiment	the	cytosolic	Ca2+	remained	high	while	FRET	gradually	
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increased	over	a	period	of	several	minutes.	This	observation	was	surprising	as	I	only	expected	to	detect	phase	1	low	FRET	of	SERCA	population	accumulated	in	the	slow	step	of	Ca2+	release	(Fig.	38A,	E2P).	I	confirmed	my	observation	in	a	muscle	reconstituted	setup	when	Iono	was	applied	to	cells	after	detection	of	anti-correlated	FRET/Ca2+	changes	and	caused	both	the	initial	low	FRET	phase	1	and	the	following	high	FRET	phase	2	(Fig.	19A).	I	propose	several	possible	explanations	for	the	phase	2	FRET	change	in	Iono-treated	cells.	
	
Figure	38.	WT-SERCA	population	accumulates	in	states	prior	to	slow	steps	during	
sustained	Ca2+	increase.	Schematic	representation	of	simultaneous	FRET	and	cytosolic	Ca2+	fluctuations	as	detected	in	Fig.	19A	is	on	the	left,	while	corresponding	transitional	steps	are	highlighted	by	blue	arrows	on	the	Post-Albers	cycle	(left	panels).	(A)	Upon	Iono	treatment,	phase	1	FRET	decrease	(open	conformers)	are	observed	due	to	accumulation	of	WT-SERCA	in	E2P	step	of	enzymatic	cycle.		(B)	Phase	2	FRET	increase	(closed	conformers)	of	WT-SERCA	during	sustained	Ca2+	increase	are	observed	due	to	accumulation	of	WT-SERCA	in	E1-2Ca-ADP	bound	step	of	enzymatic	cycle.		
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First,	Iono	application	as	low	as	2	μM	has	been	shown	to	activate	Ca2+/H+	exchangers	and	increase	intracellular	pH	due	to	Ca2+	influx	(Yamada	et	al.,	1996).	Fluorescent	proteins	are	known	to	be	highly	sensitive	to	pH	outside	of	cellular	levels	range	(Schmitt	et	al.,	2014).	Therefore,	an	increase	in	intracellular	pH	(alkalinization)	could	affect	fluorescent	proteins	and	result	in	non-relevant	FRET	change.	Nevertheless,	the	experiment	with	Cer-SERCA	and	YFP-SERCA	(Fig.	20C)	did	not	detect	intermolecular	FRET	change	upon	addition	of	Iono.	This,	it	is	unlikely	that	cell	alkalinization	was	the	direct	cause	of	observed	phase	2	FRET	change.	Second,	luminal	Ca2+	accumulation	have	been	shown	to	inhibit	SERCA	in	a	non-active	state	(Inesi	and	de	Meis,	1989).	Nevertheless,	I	detected	slow	accumulation	of	Ca2+	in	ER	lumen	after	Iono	treatment,	much	slower	than	phase	2	FRET	change	(Fig.	21A).	Therefore,	I	do	not	believe	that	the	luminal	Ca2+	may	inhibit	SERCA	in	non-active	state.	Third,	I	cannot	exclude	inhibition	of	SERCA	cycling	by	the	ADP	build-up	(Inesi	and	de	Meis,	1989)	as	ADP	to	ATP	ratio	was	shown	to	be	dramatically	increased	upon	cells	perturbation	(up	to	100	times)	due	to	distortion	of	the	mitochondrial	membrane	(Tantama	et	al.,	2013).	Therefore,	SERCA	activation	may	gradually	deplete	ATP	and	increase	ADP	levels	in	Iono-treated	cells,	which	would	shift	SERCA	population	into	non-physiological	high	Ca2+/ADP	bound	state	(Fig.	38B,	E1-2Ca-ADP)	which	is	consistent	with	observed	high	FRET	(~15%)	in	ligand-stabilized	conformations	E1-2Ca-ADP-AlF4−	(Fig.	15B	and	16).	To	summarize,	in	the	cells	with	low	basal	Ca2+	and	high	ATP	levels,	SERCA	accumulates	in	E1-ATP	high	FRET	state	(compact	conformation).	During	temporary	cytosolic	Ca2+	elevation,	SERCA	population	progresses	through	E1-2Ca-ATP	and	phosphoenzyme	E1P-2Ca	states	and	accumulates	in	the	slow	E2P	low	FRET	states	(open	
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conformers),	which	is	the	main	and	novel	funding	of	current	project.	Thus,	in	physiological	conditions	during	contractions	of	cardiac	or	skeletal	muscle	cells,	majority	of	the	actively	cycling	SERCA	population	has	an	open	headpiece	conformation.		
Structural	Dynamics	of	AAA-SERCA,	the	Nβ5-β6	Loop	Mutant,	During	Ca2+	Transport	The	experiments	with	AAA-SERCA,	which	has	key	residues	of	the	Nβ5-β6	loop	mutated,	allowed	the	understanding	of	the	SERCA	conformers’	redistribution	during	Ca2+	cycling	in	the	presence	of	a	defective	headpiece	closure	mechanism.	Even	though,	I	observed	AAA-SERCA	phase	1	FRET	decrease	after	Iono	application	similar	to	WT,	the	subsequent	recovery	and	accumulation	of	SERCA	in	high	FRET	state	was	not	achieved	(Fig	17C	and	19C).	These	data	indicate	that	AAA-SERCA	population	was	accumulating	in	a	specific	for	AAA-SERCA	slow	step,	E2	low	FRET	states	(open	conformers),	and	was	not	able	to	progress	to	E1	high	FRET	states	(compact	conformers)	due	to	decreased	kinetics	of	structural	transition	from	open	to	closed	headpiece	conformations	(Fig.	39).		 Based	on	these	results,	I	was	surprised	to	observe	AAA-SERCA	FRET	change	kinetics	similar	to	WT	during	spontaneous	Ca2+	release	events	(Fig.	18D).	I	speculate	that	while	overexpressed	AAA-SERCA	has	a	deficit	in	obtaining	closed	conformation,	endogenous	SERCA	sequesters	Ca2+	back	into	ER	lumen	while	Na2+/Ca2+	exchangers	and	plasma	membrane	Ca2+	ATPases	remove	Ca2+	from	the	cell,	which	results	in	cytosolic	Ca2+	levels	decrease.	Thus,	when	intracellular	Ca2+	levels	return	to	basal	level,	AAA-SERCA	population	redistributes	back	to	the	resting	E1-ATP	high	FRET	state	(Fig.	16,	E1-ATP).	This	statement	is	supported	by	the	observed	AAA-SERCA	FRET	decease	in	response	to	transient	elevations	of	Ca2+	upon	RyR	inhibitor	Caf	treatment,	and	following	the	increase	in	FRET	as	Ca2+	gets	
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exported	from	the	cell,	supposedly	via	Na2+/Ca2+	exchangers	and	plasma	membrane	Ca2+	ATPases	(Fig.	19D).	To	summarize,	when	AAA-SERCA	is	exposed	to	persistent	elevation	of	Ca2+,	like	upon	Iono	treatment,	the	defective	in	opened-to-closed	transition	pumps	accumulate	in	a	new	and	AAA-SERCA	specific	slow	step,	E2	low	FRET	states	(open	conformers).	As	a	consequence,	phase	2	FRET	recovery	is	not	observed	(Fig.	17C	and	17C).		
The	Nβ5-β6	Loop	as	a	Determinant	of	SERCA	Structural	Dynamics	and	Function	Previously,	Dr.	Nikolai	Smolin	had	predicted	that	the	SERCA	Nβ5-β6	loop	plays	an	important	role	in	SERCA	headpiece	transition	from	open-to-closed	conformation	(Smolin	and	Robia,	2015a).	Specifically,	salt	bridges/H-bonds	between	the	Nβ5-β6	loop	acidic/negative	residues	(Asp426,	Glu429,	and	Glu435)	and	basic/positive	residues	of	the	A-domain	(residues133-139)	were	predicted	to	initiate	the	contact	between	N-	and	A-
	
Figure	39.	AAA-SERCA	population	accumulates	in	a	new	state	prior	to	slow	step	
during	sustained	Ca2+	increase.	Schematic	representation	of	simultaneous	FRET	and	cytosolic	Ca2+	fluctuations	as	detected	in	Fig.	19C	is	on	the	left,	while	corresponding	transitional	steps	are	highlighted	by	blue	arrows	on	the	Post-Albers	cycle	(left	panels).	Upon	Iono	treatment,	AAA-SERCA	population	accumulates	in	E2	low	FRET	state	(open	conformers)	due	to	AAA-SERCA	structural	deficit	in	headpiece	closure,	a	new	slow	step	of	enzymatic	cycle.		
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domains	and	subsequent	closure	of	the	headpiece.	The	current	study	was	designed	to	investigate	a	role	of	the	Nβ5-β6	loop	in	the	SERCA	dynamics	during	Ca2+	transport	and	transporter	function.	To	prevent	the	formation	of	the	salt	bridges/H-bonds	between	Nβ5-
β6	loop	and	the	A-domain,	I	designed	triple	Alanine	mutant	of	these	three	negatively	charged	residues	(AAA)	or	point	mutants	(Asp426Ala,	Glu429Ala,	and	Glu435Ala).	Generated	SERCA	constructs	were	used	to	analyzed	SERCA	structure	and	function	during	Ca2+	transport.	The	all-atoms	MD	simulations	showed	that	even	though	AAA-SERCA	had	conserved	overall	structural	integrity	(Fig.	8-9),	it	was	deficient	in	headpiece	closure	(Fig.	10)	and	had	reduced	structural	dynamics	(Fig.	11).	Interestingly,	mutation	of	just	one	of	the	Nβ5-β6	loop	residues	was	not	sufficient	to	induce	these	detrimental	changes;	although,	Glu429	may	have	a	more	prominent	role	in	A-	and	N-domains	closure	than	other	two	residues	(Fig.	10D).	Overall,	my	MD	simulations	indicated	that	the	Nβ5-β6	loop	facilitate	SERCA	structural	transition	to	compact	headpiece	conformation	and	regulate	transporter	structural	dynamics.	The	in	silico	results	were	confirmed	by	ex	vivo	measurements	of	SERCA	structural	dynamics	by	FRET,	which	detected	a	deficit	in	SERCA	triple	loop	mutant	transition	from	open-to-closed	conformation	(Fig.	17C).	Again,	the	point	loop	mutants	showed	similar	to	WT-SERCA	kinetics	during	transition	from	open-to-closed	conformation	(Fig.	17D).	Since	I	detected	AAA-SERCA	population	in	a	low	FRET	state	with	application	of	TG	similar	to	WT(Fig.	17B),	I	excluded	global	defects	in	transporter	structure	upon	Nβ5-β6	loop	mutations	and	attributed	AAA-SERCA	deficiency	in	headpiece	closure	to	a	specific	role	of	the	Nβ5-β6	loop	negative	residues.	
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I	revealed	functional	significance	of	the	SERCA	Nβ5-β6	loop	in	ATPase	assay	by	detecting	a	63%	reduction	in	SERCA	maximal	ATPase	activity	for	AAA-SERCA	compared	to	WT	transporter	(Fig.	15A,	C).	Detected	decline	of	SERCA	function	was	not	attributed	to	the	reduction	in	Ca2+	affinity	as	mutated	transporter	binds	Ca2+	with	similar	to	WT	apparent	affinity	(Fig.	15B).	I	propose	that	detected	functional	deficit	in	SERCA	ATPase	activity	is	a	direct	consequences	of	AAA	mutant	deficit	in	structural	transition	from	opened	to	closed	headpiece	conformation.	Overall,	I	identified	the	SERCA	Nβ5-β6	loop	as	a	determinant	of	SERCA	structural	dynamics	and	function	by	presenting	evidence	that	the	Nβ5-β6	loop	facilitates	closure	of	SERCA	headpiece	and	regulates	ATPase	activity.		
Structural	Dynamics	of	SERCA-PLB	Complex	Previous	MD	simulation	by	my	lab	predicted	that	the	SERCA	Nβ5-β6	loop	can	interact	with	PLB	cytoplasmic	domain.	(Smolin	and	Robia,	2015a).	Here	I	performed	additional	MD	simulations	to	confirm	that	interaction	between	the	SERCA	Nβ5-β6	loop	and	PLB	was	stabilized	throughout	the	MD	trajectories	and	independent	of	loop	mutations	(Fig.	22F)	or	PLB	phosphorylation	(Fig.	24A-B).	Additionally,	the	SERCA	structure	was	stabilized	by	association	with	PLB	as	detected	by	reduction	in	RMSF	N-domain	(Fig.	8D	vs.	23B)	and	in	
vitro	(Fig.	30),	which	indicates	that	PLB	induces	more	compact	SERCA	conformation	as	proposed	by	my	lab	previously	(Bidwell	et	al.,	2011).	I	speculate	that	the	induction	of	more	ordered	SERCA	headpiece	conformation	may	be	a	result	of	overall	structural	stabilization	by	PLB.	In	support	to	this	statement,	I	observed	positive	correlation	between	motions	of	the	PLB	cytosolic	domain	and	the	SERCA	headpiece	domains	(Fig.	25),	as	well	as	increase	in	SERCA	intramolecular	motions	as	represented	by	predominantly	red	color	(positive	
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correlation)	of	SERCA-PLB	covariance	matrixes	(Fig,	25)	versus	white	color	(no	correlation)	of	SERCA	alone	(Fig.	9).	Even	though	I	did	not	detect	a	particular	effect	of	Ser16	phosphorylation	on	SERCA	headpiece	structural	dynamics	(Fig.	23	and	24G-H),	I	resolved	structural	rearrangements	within	the	SERCA	TM-domain	upon	phosphorylation.	Ser16	phosphorylation	induced	a	slight	shift	of	PLB	from	the	SERCA	TM-helix	M2	toward	helix	M9	(Fig.	26A-B)	at	the	same	time	as	the	Ca2+	transport	site	II	was	increased	by	displacement	of	gating	residue	Glu309	by	0.7	Å,	which	may	be	a	substantial	structural	rearrangements	to	accommodate	passage	of	1.14	Å	Ca2+	ion.	This	observation	supports	SERCA	relief-of-inhibition	subunit	model,	which	states	that	upon	phosphorylation	PLB	shifts	to	a	new	position	on	the	SERCA	TM-domain	(Bidwell	et	al.,	2011;	Negash	et	al.,	2000).	Additionally,	I	demonstrated	that	like	sarcolipin	(Autry	et	al.,	2016),	PLB	can	induce		structural	rearrangements	in	the	Ca2+	transport	site	II	by	displacement	of	gating	residue	Glu309,	possibly	for	accommodation	of	Ca2+	ion	passage.	Overall,	these	data	demonstrate	that	phosphorylation	of	the	cytosolic	PLB	domain	induces	SERCA	compact	conformation	and	structural	rearrangements	within	the	SERCA	TM-domain,	which	most	likely	has	functional	significance	for	efficient	Ca2+	transport.	When	I	examined	changes	within	PLB	itself,	I	detected	that	PLB	phosphorylation	introduced	a	kink	in	the	area	of	the	phosphorylation	site	Ser16	(Fig.	27),	increased	separation	of	the	PLB	TM-	and	cytosolic	domains	(Fig.	27	D-G),	and	oriented	PLB	more	upward	(Fig.	28F-H).	At	the	same	time	Ser16	phosphorylation	resulted	in	an	increase	of	PLB	overall	structural	organization	(Fig.	28).	I	propose	that	these	specific	changes	in	PLB	structure	are	the	preceding	cause	of	changes	in	SERCA	TM-domain.	This	statement	is	
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supported	by	the	report	that	PLB	phosphorylation	alters	structure	of	the	SERCA-PLB	regulatory	complex	(Hou	et	al.,	2008).	In	summary,	I	propose	that	SERCA	overall	structure	is	stabilized	by	association	with	PLB,	and	structural	reorganization	of	PLB	upon	Ser16	phosphorylation	results	in	PLB	displacement	from	SERCA	M2-	toward	M9-helix.	As	a	consequence,	SERCA	TM-domain	Ca2+	transport	site	II	is	able	to	accommodate	Ca2+	passage,	leading	to	SERCA	activation.		 	
2-color	ATPases	as	Biosensors	for	Identification	of	Regulatory	Interactions	SERCA	targeting	in	cardiac	dysfunctions	is	aimed	at	increasing	SERCA	activity	which	is	predicted	to	improve	cardiac	function	(Hayward	et	al.,	2015;	Inesi	et	al.,	2008).	Thus,	it	is	important	to	identify	and	characterize	SERCA	direct	regulators.		My	lab	has	successfully	used	the	2-color	SERCA	pump	to	investigate	transporter	structural	dynamics,	function,	and	regulatory	interactions	(Blackwell	et	al.,	2016;	Gruber	et	al.,	2014;	Hou	et	al.,	2012).	I	utilized	2-color	SERCA	as	a	tool	to	investigate	SERCA	interactions	with	proposed	direct	regulators	of	SERCA	activity:	HAX-1	and	DWORF.		 HAX-1	has	been	shown	to	directly	interact	with	SERCA	in	vitro	(Vafiadaki	et	al.,	2009),	but	no	evidence	has	been	reported	for	this	interaction	in	vivo.	My	measurements	with	acceptor-sensitized	and	acceptor	photobleaching	FRET	in	live	cells	detected	a	decrease	in	FRET	values	in	the	presence	of	HAX-1	(Fig.	33),	confirming	HAX-1	direct	binding	to	SERCA.	It	is	worthwhile	to	indicate	that	for	the	2-color	SERCA,	the	YFP	fusion	site	on	the	SERCA	N-domain	before	residue	509	is	too	close	to	the	proposed	Hax-1	binding	site	(residues	E575-V594)	(Vafiadaki	et	al.,	2009;	Vandecaetsbeek	et	al.,	2011).	Thus,	binding	of	Hax-1	to	this	site	on	the	N-domain	could	result	in	Hax-1	being	physically	in	the	
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way	of	measuring	true	FRET	values.	Nevertheless,	this	detail	does	not	disprove	the	demonstrated	direct	interaction	of	HAX-1	and	SERCA.			 Another	SERCA	proposed	regulator	is	DWORF,	a	recently	identified	micropeptide	encoded	by	lncRNA.	It	has	been	proposed	that	DWORF	binds	to	SERCA	in	the	same	binding	groove	as	SERCA	inhibitor	PLB	and	relieves	SERCA	inhibition	by	displacement	of	PLB	(Nelson	et	al.,	2016).	I	investigated	the	details	of	SERCA-DWORF	regulatory	interaction	by	utilizing	2-color	SERCA	in	live	cell	FRET	measurements.	I	confirmed	direct	DWORF	interaction	with	SERCA	(Fig.	34D)	and	detected	a	higher	DWORF	apparent	affinity	to	SERCA	compared	to	PLB	(Fig.	35C).	The	competition	FRET	experiments	indicated	that	DWORF	competes	with	PLB	for	SERCA	binding	(Fig.	35A).	Since	I	did	not	detect	DWORF-PLB	oligomerization	(Fig.	34G),	I	can	exclude	the	possibility	that	PLB	is	sequestered	into	heterodimers	and	the	observed	decrease	in	FRET	between	SERCA-PLB	is	due	to	true	competition	with	DWORF	for	a	binding	site.	These	results	make	DWORF	a	promising	target	for	gene	therapy	to	enhance	SERCA	activity	and	thus	improve	cardiac	function.	I	noted	that	it	was	hard	to	compete	PLB	off	with	increasing	DWORF	levels	(the	decrease	in	maximal	FRET	was	not	proportional	to	an	increase	in	DWORF	construct	expressed)	(Fig.	35D-E).	This	observation	suggests	that	when	PLB	gets	competed	away	from	SERCA	and	its	free	concentration	increases,	it	attains	higher	affinity	for	SERCA	(Fig.	35F),	which	should	be	taken	into	consideration	if	DWORF	is	to	be	used	in	gene	therapy.		 Utilization	of	2-color	SERCA	FRET	sensor	in	this	work	and	multiple	other	studies	is	aimed	to	determine	SERCA	structural	dynamics	(Blackwell	et	al.,	2016;	Hou	et	al.,	2012;	Pallikkuth	et	al.,	2013)	and	potential	substrates	(Cornea	et	al.,	2013;	Gruber	et	al.,	2014).	It	has	been	shown	that	the	technique	to	generate	2-color	FRET	biosensor	can	be	applied	to	
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other	molecules.	For	example,	2-color	MRP-1,	another	transporter	ATPase,	was	generated	and	used	in	high-throughput	screening	to	identify	potential	substrates	(Iram	et	al.,	2015).	Here,	I	confirmed	that	several	of	the	compounds	identified	as	hits	were	MRP-1	modulators,	among	which	I	recognized	a	novel	MRP-1	inhibitor,	the	vitamin	D	analog-	calcipotriol	(Fig.	36).	This	discovery	can	potentially	explain	the	mechanism	of	action	by	which	vitamin	D	has	been	demonstrated	to	potentiate	the	effect	of	chemotherapeutic	agents	(Ma	et	al.,	2010).	In	summary,	2-color	FRET	sensors	have	proved	to	be	an	effective	tool	in	investigation	of	various	transporters	structural	dynamics,	regulatory	interaction,	identification	of	novel	substrates,	and	analysis	of	ATPase	function.	Utilization	of	2-color	FRET	biosensors	is	a	promising	tool	for	the	high-throughput	screening	assays	that	are	important	in	the	drug	discovery	field	(Cornea	et	al.,	2013;	Gruber	et	al.,	2014;	Iram	et	al.,	2015).			
Clinical	Implications	SERCA	regulates	Ca2+	handling	in	cardiac	cells	by	sequestering	Ca2+	from	cytosol	into	SR	lumen,	which	allows	heart	relaxation	and	also	restores	SR	Ca2+	load	and	determines	heart	contractile	force	(Fig.	1)	(Bers,	2006;	Gwathmey	et	al.,	1987).	SERCA	is	an	attractive	target	for	improving	cardiac	function	in	heart	failure	patients	(Roe	et	al.,	2015).	In	heart	failure	a	deficiency	in	SERCA	levels	and	function	has	been	reported	(Hasenfuss	and	Pieske,	2002;	Hasenfuss	et	al.,	1994).	Restoration	of	SERCA	levels	in	various	models	of	heart	failure	has	been	shown	to	improve	cardiac	performance	of	failing	cardiomyocytes	and	hearts	(Kho	et	al.,	2012).	Nevertheless,	latest	human	clinical	studies	failed	to	significantly	improve	clinical	outcome	of	heart	failure	patients,	presumably	due	to	the	viral	delivery	failure	(Greenberg	et	al.,	2016;	Hayward	et	al.,	2015).	The	alternative	
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reason	for	gene	therapy	failure	could	be	that	solely	an	increase	in	SERCA	levels	is	not	enough	to	override	the	regulatory	processes	of	failing	heart.	Instead,	enhancing	SERCA	function	and	positive	regulation	are	alternative	strategies	for	improving	cardiac	output	in	heart	failure	patients.	Thus,	it	is	extremely	important	to	understand	details	of	SERCA	function	and	regulation.	SERCA	function	and	regulation	have	been	under	investigation	for	decades.	Nevertheless,	only	few	SERCA	specific	activators	have	been	identified	so	far	(Cornea	et	al.,	2013;	Dahl,	2017;	Kang	et	al.,	2016).	Small	molecular	allosteric	activators	of	SERCA	have	been	shown	to	increase	SERCA	Ca2+	transport	to	relive	ER	stress	and	attenuate	apoptosis	and	mitochondrial	dysfunction	(Dahl,	2017;	Kang	et	al.,	2016).	However,	the	mechanisms	of	action	for	SERCA	pharmacological	activators	are	still	not	described.	Based	on	the	FRET	method	used	for	initial	high-throughput	screening	in	identification	of	these	compounds	(Cornea	et	al.,	2013;	Gruber	et	al.,	2014),	I	reason	that	binding	of	small-molecule	activators	results	in	SERCA	cytosolic	headpiece	structural	rearrangement.	Thus,	understanding	of	the	SERCA	structural	dynamics	upon	binding	of	pharmacological	activators	is	important	for	the	rational	design	of	SERCA	novel	activators.	This	study	provided	ample	details	of	SERCA	structural	dynamics	during	Ca2+	transport	cycle	to	enhance	scientific	understanding	of	SERCA	function.	Specifically,	I	described	SERCA	structural	dynamics	in	regard	to	slow	steps	of	Ca2+	transport.		Ultimately,	designing	small-molecules	which	facilitate	SERCA	‘fast’	transition	through	these	relatively	slow	steps	that	I	described	can	enhance	SERCA	function	and	become	beneficial	for	improving	cardiac	function.	
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Additionally,	I	have	identified	and	investigated	one	of	SERCA	functional	determinant,	the	Nβ5-β6	loop.	The	Nβ5-β6	loop	facilitates	SERCA	structural	transition	from	opened	to	closed	conformations,	which	is	one	of	the	fundamental	steps	of	SERCA	enzymatic	cycle.	I	predict	that	enhancing	SERCA	cycling	‘speed’	would	allow	boosted	Ca2+	transport	and	result	in	improved	cardiac	function.	Since	I	showed	that	the	Nβ5-β6	loop	facilitate	A-	and	N-domains	closure,	I	propose	that	a	small	pharmacological	molecule	that	is	designed	to	interact	with	this	loop	and	simultaneously	serve	as	an	extension	of	this	structure	even	further	toward	A-domain,	could	allow	more	efficient	cytosolic	headpiece	closure	and	enhanced	cycling.	Overall,	this	project	provided	insights	into	SERCA	structural	transitions	through	catalytic	cycle,	including	identification	of	the	SERCA	novel	structural	and	functional	determinant,	the	Nβ5-β6	loop.	These	insights	contribute	to	understanding	of	SERCA	function	and	provide	novel	justifications	for	design	of	SERCA	small	molecular	activators.		
Limitations	of	Current	Study	In	present	work	I	utilized	a	variety	of	techniques,	including	in	silico,	in	vitro,	and	ex	
vivo	measurements.	There	are	several	limitations	in	each	of	these	techniques	that	I	had	encountered.	For	example,	I	performed	MD	simulations	for	SERCA	spontaneous	motions	for	WT	and	mutants	up	to	100	ns	due	to	limited	resources	of	computer	time	available	to	perform	MD	runs.	This	short	timescale	excludes	a	variety	of	structural	changes	that	are	happening	on	a	much	longer	timeline.	Recently,	MD	studies	of	SERCA	structural	dynamics	as	long	as	1	µs	were	conducted	(Espinoza-Fonseca	et	al.,	2015b;	Espinoza-Fonseca	and	Ramirez-Salinas,	2015;	Fernandez-de	Gortari	and	Espinoza-Fonseca,	2017)	and	MD	
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simulations	at	1	µs	timescale	are	much	anticipated	in	scientific	publications.	Nevertheless,	I	was	able	to	resolve	specific	differences	induced	by	loop	mutations	for	all	SERCA	structures	in	a	short	100	ns	timeline.	However,	I	had	a	setback	in	investigation	of	SERCA-PLB	complex	structural	dynamics	upon	PLB	Ser16	phosphorylation	due	to	limitation	of	computer	time	resources.	Specifically,	the	differences	detected	between	Ser16	and	the	A-domain	number	of	contacts	for	SERCA-PLB	and	SERCApS16	complexes	at	100	ns	MD	simulation	runs	(Fig.	22E)	became	opposing	at	200	ns	(Fig.	24C).	This	is	not	surprising,	considering	that	in	physiological	conditions	structural	changes	such	as	SERCA	headpiece	closure	or	Ca2+	ion	transport	are	predicted	to	take	place	on	a	µs-scale.	Thus,	my	studies	are	limiting	to	the	detection	of	short-lived	events	and	do	not	include	the	full	spectrum	of	spontaneous	structural	changes.	Due	to	this	limitation,	I	decided	to	supplement,	and	in	this	way	strengthen,	my	MD	simulations	data	with	physical	experiments.	The	basis	for	FRET	technique	have	been	established	70	years	ago	(Förster,	1948)	and	up-to-date	this	assay	plays	a	major	role	in	detection	and	characterization	of	proteins’	inter-	and	intramolecular	structural	changes.	The	structural	dynamics	of	2-color	SERCA	captured	by	acceptor	photobleaching	and	acceptor-sensitized	emission	FRET	measurements	have	been	well	characterized	(Bidwell	et	al.,	2011;	Hou	et	al.,	2012;	Smolin	and	Robia,	2015b).	Nevertheless,	such	measurements	only	capture	average	FRET,	which	represents	average	conformation	of	SERCA	population.	Most	likely,	SERCA	conformers	exist	in	a	significant	structural	heterogeneity	which	is	not	detected	with	these	methods.	For	example,	x-ray	crystallography	and	electron	microscopy	identified	only	one	structural	state	of	SERCA	stabilized	by	TG	(Takahashi	et	al.,	2007;	Toyoshima	et	al.,	2000;	Young	et	al.,	2001),	while	time-resolved	fluorescence	measurements	showed	that	SERCA	bound	to	TG	
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exists	in	at	least	two	conformations	(Pallikkuth	et	al.,	2013).	Thus,	my	FRET	results	do	not	report	all	the	variety	of	SERCA	conformers	which	presumably	exists.	In	this	study	I	used	muscle-like	HEK-293	cell	model	which	was	initially	developed	for	monitoring	intracellular	Ca2+	oscillations	(Bovo	et	al.,	2016).	This	model	was	supplemented	with	2-color	SERCA	and	adapted	for	simultaneous	detection	of	SERCA	FRET	and	spontaneous	Ca2+	release	events.	I	obtained	clear	traces	of	the	FRET	ratio	and	intracellular	Ca2+	oscillations	for	cells	expressing	WT-SERCA	(Fig.	18B-C.	19A-B).	Nevertheless,	cells	transfected	with	AAA-SERCA	and	exhibiting	simultaneous	FRET	change	/Ca2+	release	events	were	harder	to	find.	Additionally,	the	Ca2+	fluctuations	were	much	rare,	while	traces	were	noisier	compared	to	those	of	the	cells	expressing	WT-SERCA	(Fig.	18D,	19C-D).	This	difficulty	of	finding	‘firing’	cells	limited	my	AAA-SERCA	analysis	by	the	number	of	cells	evaluated	compared	to	WT-SERCA.	On	the	other	hand,	the	inability	to	detect	number	of	cells	with	simultaneous	FRET	and	Ca2+	fluctuations	similar	to	WT	indicates	the	deficiency	of	AAA-SERCA	to	store	Ca2+	in	the	ER	for	the	release	event,	which	I	believe	to	be	the	direct	consequence	of	AAA-SERCA	deficiency	in	structural	transitions	from	open-to-closed	conformation.	In	my	DWORF	acceptor-sensitized	FRET	detection	experiment	I	observed	a	higher	DWORF’s	apparent	affinity	to	SERCA	than	PLB	(Fig.	35C).	Nevertheless,	in	my	competition	experiments,	when	I	increased	DWORF	levels	to	outcompete	PLB	from	SERCA,	non-linear	SERCA-PLB	FRET	and	Kd	decreases	were	observed,	suggesting	that	PLB	has	higher	affinity	to	SERCA	in	the	presence	of	DWORF	(Fig.	35E-F).	This	observation	may	seems	as	contradictory	to	my	previous	observation	that	DWORF	binds	to	SERCA	better	than	PLB	(Fig.	35C).	I	believe	that	the	increased	apparent	affinity	of	PLB	to	SERCA	was	due	to	the	
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increase	of	PLB	monomers	as	a	result	of	competition	with	DWORF.	Availability	of	PLB	monomers	enhanced	PLB	ability	to	bind	to	SERCA	and	in	this	way	increased	PLB	apparent	affinity.	Ideally,	I	need	to	perform	the	competition	experiments	when	instead	of	outcompeting	PLB	with	DWORF	from	SERCA	binding	site,	I	compete	DWORF	from	SERCA	with	gradually	increasing	co-expression	of	PLB.	In	reality,	this	experiments	required	a	large	amount	of	PLB	DNA	construct	transfection,	and	cells,	overwhelmed	with	DNA	load,	became	unhealthy,	which	resulted	in	inconstant	measurements	between	experiments.	Therefore,	optimization	of	the	expression	system	is	required	to	overcome	this	limitation	for	successful	execution	of	the	PLB-DWORF	competition	experiments.	One	of	possible	strategy	could	be	the	use	of	smaller	DNA	vectors.		Another	difficulty	that	I	encountered	was	the	struggle	to	produce	functional	microsomes.	As	presented	in	Figure	15,	I	measured	WT-SERCA	FRET	in	microsomal	membrane	preparations	from	AAV-293	cells	transiently	transfected	with	SERCA	DNA	constructs.	The	FRET	increase	curve	over	increasing	Ca2+	levels	(Fig.	15A)	was	regarded	as	a	control	experiment	in	determination	if	the	microsomal	preparations	are	suitable	for	
	
	
Figure	40.	AAA-SERCA	structural	dynamics	measured	by	FRET	in	microsomes.	
(A)	AAA	2-color	SERCA	showed	steady	FRET	levels	with	Ca2+	increase.	(B)	FRET	of	AAA	2-color	SERCA	stabilized	in	key	enzymatic	states.	
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substrate-stabilized	structural	FRET	measurements	(Fig.	15B).	However,	for	AAA-SERCA	microsomal	preparations	I	constantly	observed	no	significant	FRET	response	to	increasing	Ca2+	levels	(Fig.	39A)	or	in	substrate-stabilized	structural	measurements	(Fig.	39B).	Since	I	prepared	several	batches	all	of	which	showed	this	result,	I	am	unsure	if	AAA-SERCA	headpiece	was	not	responsive	to	substrates	tested,	or	microsomal	samples	were	compromised.	Based	on	the	ATPase	curves,	AAA-SERCA	has	similar	to	WT	pump	Ca2+affinity	(Fi.	14B).	Thus,	I	believe	that	Ca2+	binds	to	mutated	transporter	and	should	induce	a	structural	response	similar	to	WT.	However,	since	AAA-SERCA	has	a	deficit	in	progression	from	open	to	closed	conformer,	I	may	only	detect	this	specific	to	AAA-SERCA	slow	step	of	enzymatic	cycle.	Thus,	the	interpretation	of	this	experiment	is	ambiguous	and	for	that	reason	it	was	not	included	in	the	main	chapter.	Overall,	I	believe	that	I	was	able	to	provide	a	complex	review	of	the	SERCA	structural	dynamics	during	Ca2+	transport	and	identified	the	Nβ5-β6	loop	as	SERCA	structural	and	functional	determinant	by	combining	in	silico,	in	vitro,	and	ex	vivo	experiments,	which	were	aimed	at	complementing	and	strengthening	each	other.		
Overall	Conclusion	The	novel	insights	and	substantial	details	of	SERCA	transient	conformations	during	Ca2+	transport	revealed	in	this	study	extend	the	scientific	understanding	of	SERCA	structural	dynamics	and	redistribution	of	SERCA	conformers	in	response	to	intracellular	Ca2+	fluctuations.	The	SERCA	Nβ5-β6	loop,	identified	as	a	structural	determinant	of	transporter	headpiece	closure	with	a	functional	implication	in	SERCA	ATPase	activity	and	Ca2+	transport,	can	become	a	promising	target	of	a	novel	small-molecule	therapeutics	aimed	to	enhance	cardiac	output	in	heart	failure	patients.	
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